Overview

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Status:
Not yet recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate the efficacy, safety & patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin.

Phase:

Phase 3

Details

Lead Sponsor:

ITM Solucin GmbH

Treatments:

Capecitabine
Edotreotide
Everolimus
Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin
Pharmaceutical Solutions
Temozolomide